35P - Clinical significance of expression of cripto-1 in patients of squamous cell carcinoma of oropharynx
|Date||17 December 2016|
|Event||ESMO Asia 2016 Congress|
|Topics|| Head and Neck Cancers
|Citation||Annals of Oncology (2016) 27 (suppl_9): ix9-ix18. 10.1093/annonc/mdw574|
M.S. Kumar1, A. Pal2, A. Jain2, S. Ghoshal1, B. Rai1, S. Mohindra3, A. Das4
Most cancers of head and neck region present in an advanced stage. Early diagnosis of the disease may improve therapeutic outcome by increasing cure rates and decreasing morbidities. A biomarker can detect these tumors at an early stage. Cripto-1(CR-1), a teratoma derived growth factor, is overexpressed in certain tumors and found in the plasma of patients. This study was planned to study the over expression and clinical significance of CR-1 in patients with oropharyngeal squamous cell carcinoma(OSCC). The aim of the study is to correlate serum CR-1 levels in patients of OSCC with clinico-pathological features and response to treatment by a) comparing CR-1 levels between patients and controls b) correlating CR-1 levels with histological grade and stage of disease and c) comparing pre and post treatment CR-1 levels and correlate with disease status.
Fifty healthy volunteers(controls) and fifty biopsy proven cases of OSCC were recruited in the study after using inclusion and exclusion criteria. All patients were treated with radical chemo-radiation and response was assessed at 6 weeks post therapy. Serum CR-1 levels were analyzed by ELISA in patients, both before and after treatment, and also in controls. Expression of CR-1 was compared between controls and patients. Pre and post treatment CR-1 levels in patients were compared and correlated with clinic-pathological findings. SPSSv16.0 was used for statistical analysis.
As compared to controls, serum CR-1 levels are significantly raised in patients with OSCC (207 pg/ml Vs 497 pg/ml, p=.003). CR-1 levels are significantly higher in patients with well differentiated and early stage tumors as compared to controls. CR-1 levels decreased significantly after treatment and correspond with response to therapy (497 pg/ml Vs 228 pg/ml, p=.046).
Human serum CR-1 is a potential tumor marker for OSCC. This study also suggests that CR-1 may be useful in early diagnosis of OSCC and merits larger, prospective studies
Clinical trial indentification
Legal entity responsible for the study
PGIMER, Chandigarh, India
All authors have declared no conflicts of interest.